Dermatology Times, May 2023 (Vol. 44. No. 05)

Learn more about the in-depth topics covered in the May 2023 issue of Dermatology Times®.

In this month’s Legal Eagle column, we delve into cases involving informed consent.

In this month’s Finance & Practice Management column, we illustrate the importance of developing and maintaining a budget for physicians at all stages of their careers.

The clinical and histologic subtypes encompassed by granulomatous dermatitis include palisaded neutrophilic granulomatous dermatitis and interstitial granulomatous dermatitis. This review compares the features of each cutaneous eruption.

The autosomal recessive disorder is primarily caused by mutations in the TGM5 gene and less frequently in the CSTA gene.

In this month’s Cosmetic Conundrums column, Zoe Diana Draelos, MD, discusses solutions for ethnic and Afro-textured hair care.

Patients with chronic conditions like alopecia areata may experience a reciprocal relationship between their condition and mental health.

Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.

Leading clinicians discuss sun protection best practices based on weather, climate, and travel needs.

Leading clinicians discuss sun protection and special issues in photosensitivity.

Leading clinicians debunk 5 of the most common sunscreen myths.

Leading clinicians discuss sun protection best practices and recommendations for the upcoming summer months.

In Dermatology Times®’ most recent Expert Perspectives series, Hot Topics in Skin Care in 2023, skin care experts met at the 2023 American Academy of Dermatology Annual Meeting to discuss their best treatment pearls.

Clinicians who provide dermatologic care know firsthand how diseases of the skin can diminish someone’s confidence and productivity.

In this month's letter from the Editor in Chief, Zoe Diana Draelos, MD, discusses the latest advances and opportunities in the field of dermatology.

According to new research, vitamin D and serum brain-derived neurotrophic factors may exacerbate depression in some dermatologic patients.

AbbVie announced study results demonstrating efficacy in patients with a history of previous interleukin-17 inhibitor therapy.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

“The present and future is narrow-spectrum antibiotics because they enhance antibiotic stewardship, they protect the host microbiome, [and] they reduce antibiotic resistance,” AAD 2023 presenter Christopher Bunick, MD, PhD, said.

Promising phase 2 data for LY3041658 released during the Late-breaking Research session at the 2023 annual meeting.

The latest phase 3 trial results were showcased in an AAD late-breaking research session.

Granulomatous dermatitis includes a group of reactive dermatologic disorders characterized by distinct histopathological patterns, clinical manifestations, and associated diseases.